The Prostate Cancer Foundation (PCF) and Exosome Diagnostics have entered into a multiyear collaboration agreement to accelerate clinical validation of Exosome’s biofluid molecular diagnostics technology in prostate cancer.

The collaboration will examine the capabilities of a new generation of RNA biofluid diagnostics for early identification, progression monitoring and advanced disease risk stratification in prostate cancer.

The aim of the project is to bring together clinicians, researchers and industry participants to explore and develop the full potential of stable, high quality disease-specific RNA, harvested from exosomes found in blood and urine samples.

The programme will support in-vitro diagnostic validation of known clinical prostate cancer biomarkers, as well as a robust biomarker discovery programme for prostate cancer from diagnosis through progression and treatment.

Exosome Diagnostics CEO James McCullough said the progressive collaboration assures they have the right people at the table on the front side of the clinical translation process to accurately assess unmet medical opportunities, properly design validation studies and deliver exosome technology benefits quickly to patients.

PCF chief science officer Howard Soule said they believe exosome technology may help improve diagnosis, therapy management and a reduction in patients suffering from prostate cancer.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.